APA (7th ed.) Citation

JM, C., C, S., D, A., A, H., O, G., M, N., . . . AM, S. (2026). Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2503128. https://doi.org/10.1200/JCO-25-03128

Chicago Style (17th ed.) Citation

JM, Cleary, et al. "Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the ENRGy Phase II Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2026: JCO2503128. https://doi.org/10.1200/JCO-25-03128.

MLA (9th ed.) Citation

JM, Cleary, et al. "Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the ENRGy Phase II Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2026, p. JCO2503128, https://doi.org/10.1200/JCO-25-03128.